Volume 129, Issue 1

Cover Figure: Highly specific therapeutic inhibitor of APC for hemophilia.  See the article by Polderdijk et al.

WASHINGTON, January 5, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

The chromatin-associated Sin3B protein is required for hematopoietic stem cell functions in mice
Cantor and David pinpoint Sin3B, a component of the mammalian Sin3-HDAC corepressor complex, as an essential factor that regulates quiescence and differentiation of long-term hematopoietic stem cells.

The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment
Muchtar and colleagues report multiparametric flow cytometry studies on the quantitative assessment of clonal plasma cell burden at diagnosis and following treatment in patients with immunoglobulin light-chain amyloidosis. They demonstrate the prognostic value of these estimates as predictors of treatment response and survival.

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
CD19-targeted therapies based on T cells expressing CD19-specific chimeric antigen receptors or CD19/CD3-bispecific T-cell engagers (BiTEs) have potent antitumor activity in patients with CD19-positive lymphoma and leukemia. Braig et al identify a novel mechanism of CD19-targeted immune escape.

Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy
Kim et al provide evidence that chronic myeloid leukemia (CML) can arise from a preexisting Philadelphia chromosome–negative hematopoietic clone already harboring additional gene mutations, which is consistent with the concept of preexistent clonal hematopoiesis in CML.

Design and characterization of an APC-specific serpin for the treatment of hemophilia
Polderdijk et al design and evaluate a therapeutic inhibitor of activated protein C. They produced a recombinant variant of α1-antitrypsin incorporating 3 residue changes within the P2-P1’ sequence of its reactive loop. This variant exhibits the desired high specificity profile and inhibitory efficiency towards activated protein C.

Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma
Du and colleagues describe a novel approach to eradicate the malignant cells of classical Hodgkin lymphoma by a combination of differentiation therapy and therapeutic targeting of the restored B-cell phenotype in preclinical cell line models.

Introduction to a review series on chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets
New directions of research discussed in this series of reviews aim at targeting B-cell signaling pathways that are operational in chronic graft-versus-host disease (cGVHD). The 3 reviews highlight novel insights into the pathogenesis and classification of cGVHD and new therapeutic strategies that have evolved over the past 5 years.

The articles in this review series, "Chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets," include the following:


This week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.